Aldosterone Blockade in Patients With Systolic Left Ventricular Dysfunction

Circulation

Volumn 108, Issue 15, 2003, Pages 1790-1794

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; EPLERENONE; FUROSEMIDE; LOOP DIURETIC AGENT; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; SIMVASTATIN; SPIRONOLACTONE;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ECHOCARDIOGRAPHY; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; IMPOTENCE; MASTALGIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; FORECASTING; HEART FAILURE, CONGESTIVE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0142117284     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000086776.15268.22     Document Type: Review

References (27)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Weber M. Clinical implications of aldosterone blockade. Am Heart J. 2002;144(suppl 5):S12-S18.
4. Pitt B, Reichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Circulation. In press.
5. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
6. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart. 2001;85:E8.
7. Georges B, Beguin C, Jadoul M. Spironolactone and congestive heart failure. Lancet. 2000;355:1369-1370.
8. McMullan R, Silke B. Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. Ulster Med J. 2001;70:111-115.
9. Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
10. Tamirisa K, Aaronson K, Cody R, et al. Spironolactone-induced renal impairment and hyperkalemia in patients with heart failure: can we predict these side effects? J Am Coll Cardiol. 2003;41(suppl 6):162A.
11. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
12. Cooper H, Dries D, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-1315.
13. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
14. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:1722-1728.
15. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2002;37:1800-1807.
16. Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001;141:41-46.
17. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
18. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep. 2001;3:240-248.
19. Funder J. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J. 2002;144:S8-S11.
20. Liew D, Krum H. The role of aldosterone receptor blockade in the management of cardiovascular disease. Curr Opin Investig Drugs. 2002;3:1468-1473.
21. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344.
22. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000;57:1408-1411.
23. Rocha R, Williams G. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62:723-731.
24. Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am. 2003;87:441-457.
25. Virdis A, Neves M, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
26. Zhang Z, Francis J, Weiss R, et al. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol. 2002;283:H423-H433.
27. Weber K. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.